Cargando…

Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study

Vortioxetine is approved for the treatment of adults with major depressive disorder. This open-label extension (OLE) study evaluated the safety and tolerability of vortioxetine in the long-term treatment of major depressive disorder patients, as well as evaluated its effectiveness using measures of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacobsen, Paula L., Harper, Linda, Chrones, Lambros, Chan, Serena, Mahableshwarkar, Atul R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525811/ https://www.ncbi.nlm.nih.gov/pubmed/26020712 http://dx.doi.org/10.1097/YIC.0000000000000081

Ejemplares similares

Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
por: Alam, Mohammed Y., et al.
Publicado: (2014)

The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
por: Baldwin, David S, et al.
Publicado: (2016)

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder
por: Mahableshwarkar, Atul R, et al.
Publicado: (2015)

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD
por: Mahableshwarkar, Atul R., et al.
Publicado: (2015)

Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study
por: Mattingly, Gregory, et al.
Publicado: (2023)

An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder
por: Shah, Anish, et al.
Publicado: (2018)

A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus
por: Yang, Sae Jeong, et al.
Publicado: (2021)

A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders
por: Findling, Robert L., et al.
Publicado: (2018)

Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study
por: Peters-Strickland, Timothy, et al.
Publicado: (2015)

Efficacy and safety of 40 mg or 60 mg duloxetine in Japanese adults with diabetic neuropathic pain: Results from a randomized, 52‐week, open‐label study
por: Yasuda, Hitoshi, et al.
Publicado: (2015)

Effectiveness of Lurasidone 80 mg in Patients with Schizophrenia: Results of an Open-Label, 12-Week Extension Study
por: Miura, Itaru, et al.
Publicado: (2022)

Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study
por: Saito, Takuya, et al.
Publicado: (2022)

Design of a real-world, prospective, longitudinal, observational study to compare vortioxetine with other standard of care antidepressant treatments in patients with major depressive disorder: a PatientsLikeMe survey
por: Raveendran, Subhara, et al.
Publicado: (2023)

Polyethylene glycol 3350 plus electrolytes for chronic constipation: a 2-week, randomized, double-blind, placebo-controlled study with a 52-week open-label extension
por: Nakajima, Atsushi, et al.
Publicado: (2019)

Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder
por: Boulenger, Jean-Philippe, et al.
Publicado: (2014)

Is 2-dimensional transvaginal ultrasonography necessary 6 weeks after insertion of the levonorgestrel 52-mg intrauterine device?
por: van der Heijden, Patty A.H.H., et al.
Publicado: (2022)

52 Procedures in 52 Weeks: An Innovative Curriculum for Emergency Medicine Residents
por: Walsh, Ryan, et al.
Publicado: (2017)

The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study
por: Yataba, Ikuko, et al.
Publicado: (2016)

Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study
por: Landy, Stephen, et al.
Publicado: (2018)

The effect of vortioxetine on overall patient functioning in patients with major depressive disorder
por: Florea, Ioana, et al.
Publicado: (2017)

A Critical Role of Mitochondria in BDNF-Associated Synaptic Plasticity After One-Week Vortioxetine Treatment
por: Chen, Fenghua, et al.
Publicado: (2018)

OR23-05 Log-term Efficacy And Safety Of Transcon PTH In Adults With Hypoparathyroidism: 52-week Results From The Open-label Extension Of The Phase 3 Pathway Trial
por: Clarke, Bart, et al.
Publicado: (2023)

Vortioxetine: Clinical Pharmacokinetics and Drug Interactions
por: Chen, Grace, et al.
Publicado: (2017)

Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients
por: Findling, Robert L., et al.
Publicado: (2017)

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
por: Miao, Jia, et al.
Publicado: (2019)

Vortioxetine as adjunctive therapy in the treatment of schizophrenia
por: Redaelli, Sofia, et al.
Publicado: (2022)

Clinical effectiveness of vortioxetine in postcovid syndrome
por: Vikarenko, M., et al.
Publicado: (2022)

The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials
por: Li, Guangjian, et al.
Publicado: (2016)

The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis
por: Zheng, Jiahuan, et al.
Publicado: (2019)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension
por: Lipton, Richard B, et al.
Publicado: (2020)

The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study
por: Bae, Sang-Cheol, et al.
Publicado: (2022)

An open-label, randomized controlled trial of sulfamethoxazole–trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up
por: Utsunomiya, Masako, et al.
Publicado: (2020)

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial
por: Ailani, Jessica, et al.
Publicado: (2020)

Crystal structures of vortioxetine and its methanol monosolvate
por: Zhou, Xin-Bo, et al.
Publicado: (2015)

Which Cognitive Domains are Improved by Treatment with Vortioxetine?
por: Harrison, John E, et al.
Publicado: (2016)

Vortioxetine improves cognition in mild cognitive impairment
por: Tan, Sheng Neng, et al.
Publicado: (2021)

RisksAssociated with Vortioxetine in the Established Therapeutic Indication
por: Verma, Akansha, et al.
Publicado: (2021)

Vortioxetine Improved Depressive State In Parkinson’s Disease
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mvuatea25hrs1boegn4re6rf4i